A large observational study finds that once-daily umeclidinium-vilanterol dry powder inhaler significantly reduces COPD exacerbation risk compared to glycopyrrolate-formoterol and tiotropium-olodaterol, while maintaining similar safety profiles across all three dual bronchodilator therapies.